Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of Entrepreneurs in Residence (EIRs): Kia Motesharei, Ph ...

Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

Any thoughts on milk thistle supplements in fatty liver disease that was diagnosed by an ultrasound due to elevated AST and ...

I’ve no history of nosebleeds, but over the past five weeks, I’ve had five. The first three times, the bleeding stopped after ...

Any thoughts on milk thistle supplements in fatty liver disease that was diagnosed by an ultrasound due to elevated AST and ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including American Express Co. (AXP), NextEra ...

New technology and drugs are transforming how doctors detect and treat silent liver disease MASLD before it leads to liver ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), with a market capitalization of approximately $5.9 billion, has been making waves in the pharmaceutical industry with its flagship drug Rezdiffra, ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), with a market capitalization of approximately $5.9 billion, has been making waves in the pharmaceutical industry with its flagship drug Rezdiffra ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with liver disease. The company presented positive two-year results from the open ...

“Rezdiffra demonstrated broad, sustained efficacy across multiple noninvasive parameters at two years of treatment. A high, statistically significant percentage of patients with CSPH or probable ...